Moreover, 62 serum samples from healthy volunteers were collected. Clinical characteristics of study population are shown in Table 1. Serum samples were stored −30°C

until use. All type 1 AIH patients underwent liver biopsy. All of type 1 AIH patients, DILI patients, and PSC patients were seronegative for immunoglobulin M (IgM) antibody to hepatitis A virus, IgM antibody to hepatitis B core antigen, hepatitis B surface antigen, and hepatitis C virus RNA identifiable by nested reverse transcription-polymerase chain reaction. Type 1 AIH was diagnosed based on the revised scoring system proposed by International AZD0530 mw Autoimmune Hepatitis Group.[2] None of type 1 AIH patients were positive for serum anti-liver kidney microsomal-1 autoantibodies. DILI was diagnosed based on the diagnostic criteria of the Digestive Disease Week-Japan 2004 workshop,[7] which usefulness in the diagnosis of DILI has been confirmed by the study with large sample size.[8] A diagnosis of acute hepatitis A, B, and C was made based on the presence of IgM antibody to hepatitis A virus, IgM antibody to hepatitis B core antigen, and hepatitis C virus RNA, respectively. The diagnosis of PSC was made according to accepted criteria: typical cholangiographic

findings or histological selleck chemicals llc findings of cholangitis in combination with biochemical and clinical findings.[9] Liver biopsy in type 1 AIH patients was performed before or just after commencing the initial treatment. Liver biopsy specimens were

evaluated by two pathologists (YM, KY) and diagnosed as acute or chronic hepatitis.[10] Liver biopsy specimens diagnosed as chronic hepatitis underwent histological staging based on the classification of Desmet and colleagues.[11] Aspartate As initial treatment, 43 patients (83%) received prednisolone (PSL) treatment (20–40 mg/day), and 4 patients (8%) did monotherapy of ursodeoxycholic acid. In the remaining five patients (9%), initial treatment was unknown because they were transferred to other hospitals without follow up. Initial treatment was continued until the normalization of serum alanine aminotransferase (ALT) levels (≤ 30 IU/L). After the normalization of serum ALT levels, PSL was tapered by 2.5–5 mg every 1 or 2 weeks to a maintenance dose of 10 mg/day or less. PSL was halted when normal levels of serum ALT continued at the maintenance dose for more than 2 years. Each patient underwent a comprehensive clinical review and physical examination at presentation and each follow-up visit. Conventional laboratory blood tests were performed every 1–2 months. Relapse was defined as an increase in serum ALT level to more than twofold of the upper normal limit (> 60 IU/L), following the normalization of serum ALT level with medical treatment. Approximately 30 mL of blood was obtained from a healthy volunteer in heparinized tubes.